GuidelineHepatology international2020
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19.
Guideline in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.Frontiers in bioengineering and biotechnology · 2022Pooled it
- Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association.Journal of liver cancer · 2025Article
- Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association.Annals of surgical treatment and research · 2025Article
- Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.International journal of clinical oncology · 2025Review
- Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies.JHEP reports : innovation in hepatology · 2025Article
- A Patient Charter to Improve Care for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Review
- Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.Inflammopharmacology · 2024Review
- Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma.Frontiers in immunology · 2024Article
- Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study.EClinicalMedicine · 2024Article
- Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib.The Kaohsiung journal of medical sciences · 2023Article
- Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.Hepatology communications · 2023Article
- Article
- Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.Journal of gastrointestinal cancer · 2023Review
- High frame-rate contrast enhanced ultrasound (HIFR-CEUS) in the characterization of small hepatic lesions in cirrhotic patients.Journal of ultrasound · 2023Article
- Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective.World journal of virology · 2022Review
- Impact of the COVID-19 Pandemic on the Outcomes of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Single Center Experience from a Developing Country.Medicina (Kaunas, Lithuania) · 2022Article
- Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic.Journal of interventional medicine · 2022Article
- COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.Journal of clinical medicine · 2022Review
- Organisation of cancer care in troubling times: A scoping review of expert guidelines and their implementation during the COVID-19 pandemic.Critical reviews in oncology/hematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 has been giving the devastating impact on the current medical care system. There are quite many guidelines on COVID-19, but only a few on the management of hepatocellular carcinoma (HCC) during COVID-19 pandemic.
aimsWe develop these recommendations to preserve adequate clinical practice for the management of HCC.
methodsExperts of HCC in the Asia-Pacific region exchanged opinions via webinar, and these recommendations were formed.
resultsClose contact should be minimized to reduce possible exposure of both medical staff and patients to the novel coronavirus. To prevent transmission of the virus, meticulous hygiene measures are important. With the decrease in regular medical service, the medical staff may be mobilized to provide COVID-19-related patient care. However, diagnosis and treatment of HCC should not be delayed because of COVID-19 pandemic. The management of HCC should be the same as in non-pandemic circumstances. HCC is highly malignant, thus it is recommended not to delay curative treatment such as surgery and ablation. However, a kind of triage is necessary even among patients with HCC when resources are insufficient for all to be treated. Curative treatments should be periodized and cytoreductive or non-curative treatment such as vascular interventions and systemic therapy may be postponed until it can be performed safely with sufficient resources. For patients with confirmed or suspected to be infected with the novel coronavirus, diagnosis and treatment should be postponed until the virus is eliminated or they are confirmed as not being infected with it.
conclusionsThese are collection of measures implemented by front-line medical professionals. We would evolve these recommendations over time as more real-world data becomes available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.